Menopausal estrogens and breast cancer.

Area of Science:

• Endocrinology
• Oncology
• Epidemiology

Background:

• Menopausal hormone therapy, specifically conjugated estrogens, has been widely used for symptom management.
• Long-term effects of conjugated estrogen therapy on breast cancer incidence require ongoing investigation.

Purpose of the Study:

• To evaluate the long-term incidence of breast cancer in women using conjugated estrogens for menopause.
• To assess the relationship between duration, dosage, and administration patterns of conjugated estrogens and breast cancer risk.

Main Methods:

• A cohort of 1891 women treated with conjugated estrogens for menopause was followed for a mean of 12 years.
• Breast cancer incidence was compared to expected rates in the general population, with relative risks calculated.
• Factors such as duration of use, dosage, administration frequency, parity, and oophorectomy were analyzed.

Main Results:

• An overall increased relative risk of breast cancer (1.3) was observed, rising significantly to 2.0 after 15 years.
• Higher risk was associated with higher-dose tablets and non-daily administration.
• Protective factors like multiparity and oophorectomy lost their association with reduced risk after 10 years.
• Estrogen use was linked to a particularly high risk in women who developed benign breast disease after starting the drug.

Conclusions:

• Long-term use of conjugated estrogens for menopause is associated with an increased risk of breast cancer.
• The risk appears to escalate with duration and is influenced by dosage and administration patterns.
• Conjugated estrogens may negate the protective effects of parity and oophorectomy against breast cancer in postmenopausal women.